BMJ Acceptance Rate

BMJ's acceptance rate has stayed low across a period when the journal's visibility and submission pressure changed. The selectivity signal is therefore steadier than the prestige signal.

Key trend: the acceptance-rate story is flatter than the prestige story. The current author takeaway is that BMJ remains a low-acceptance flagship, and the first screen is still about audience breadth, practice consequence, and methods readiness. It is not meaningfully up from 7% in 2024 or down from the 7-8% historical band in 2015-2016; the practical signal is a stable low acceptance band.

The practical implication: submitting in 2026 is not easier than submitting before the pandemic. A paper does not become BMJ-ready because the journal is highly cited; it becomes BMJ-ready when the conclusion matters outside one specialty lane.

Journal-visibility measures such as CiteScore and SJR can help place BMJ in the general-medicine landscape, but they are not acceptance-rate inputs. They do not predict whether an individual manuscript clears the desk screen.

BMJ's first editorial screen is not a generic quality check. The editors ask: does this finding matter at a population, clinical-practice, or policy level, not just for one narrow group of patients or specialists?

A treatment that works in a clinical trial is interesting. A treatment that changes population health outcomes is BMJ material. This distinction catches many strong clinical papers that have individual-level significance without population-level implications.

In our BMJ pre-submission reviews, the most common false-positive fit is a technically solid specialty manuscript that cites BMJ's prestige but never explains why a broad medical reader should act differently. Those papers can be publishable and still be wrong for The BMJ.

BMJ's open peer review means reviewer identity and review history are more visible than in many anonymous review systems. This creates a different review culture:

• Reviews tend to be more constructive (reviewers sign their work)

• Unreasonable demands are rare (they become part of the public record)

• Some reviewers decline because they don't want their identity attached to the review

• Finding reviewers can take longer than at anonymous journals

For authors, this means the feedback you receive is usually more carefully considered. The trade-off is that the reviewer recruitment phase can be slower.

Public prepublication histories also make the journal's expectations visible. For example, BMJ decision letters and accepted-paper histories point authors back to mc.manuscriptcentral.com/bmj for revisions, and recent BMJ research examples include DOI records such as 10.1136/bmj-2023-078276, 10.1136/bmj-2023-079089, and 10.1136/bmj-2024-079694. Those examples are not acceptance predictors, but they show the kind of full research artifact BMJ publishes after review.

The headline rate blends several very different outcomes. A paper rejected after a short editorial read, a paper declined after two rounds of peer review, and a paper transferred to another BMJ title all shape the author's experience differently.

For research articles, the 4% figure is the more sobering number. It means most manuscripts never reach a stage where the final decision turns on small writing changes. The central question is whether the abstract, methods, reporting package, and cover letter make the broad medical case immediately.

The number also hides article-type differences. BMJ publishes original research, analysis, education, opinion, and commissioned material. A research manuscript competing for a scarce research slot is not in the same queue as a commentary or commissioned educational piece.

Submit if:

• the clinical finding has population health relevance (not just individual patient impact)

• you're comfortable with open peer review (reviewer names will be public)

• no APC is important for your funding situation

• the evidence level is strong enough for the BMJ's statistical scrutiny

Think twice if:

• the clinical importance is individual-level rather than population-level

• you prefer anonymous peer review

• NEJM or the Lancet is a more natural editorial fit for the clinical question

• the finding is specialty-specific (specialty journals are a better home)

A BMJ submission readiness check can help assess whether the population health framing meets BMJ's editorial expectations.

For manuscripts targeting BMJ, three issues consistently trigger desk rejection. Each is grounded in the journal's published submission criteria, editorial commentary, and the patterns we see when reviewing clinical manuscripts before submission.

Study findings that are clinically valid but not population-relevant. BMJ's editorial standards require that research "has the potential to change practice or illuminate an important medical or scientific question." The failure pattern is a clean clinical study where the finding matters to individual patient management but has no clear population health implication.

A trial showing that drug A is 15% more effective than drug B for condition X is clinically useful; BMJ wants to know whether this changes how healthcare systems should allocate resources or whether screening policies should shift. This population-level framing is not just presentation polish: it is an editorial requirement that many strong clinical papers fail to meet.

Narrow specialty scope without general medical applicability. BMJ's own guidance states that "only research with international general interest" is considered for the flagship journal. The most direct desk rejection trigger is a paper whose introduction, methods, and discussion assume subspecialty familiarity. A paper on a highly specific surgical technique, a rare hematological disorder, or a disease with narrow geographic prevalence will be directed to a BMJ specialty journal regardless of methodological quality.

The test is simple: would a well-read general practitioner in a different country find this clinically relevant to their practice? If the answer requires substantial specialty context to be yes, the submission belongs elsewhere.

Statistical analysis that does not meet BMJ's rigor threshold. BMJ employs statistical editors who review manuscripts before peer review. Papers with unadjusted analyses where confounding is plausible, with p-values reported without effect sizes and confidence intervals, or with underpowered samples for the claimed finding, are returned before external review. The journal's statistical guidelines require that "all statistical analyses include effect sizes with 95% confidence intervals."

Papers in epidemiology must include multivariable adjustment and clearly specify model covariates. Presenting raw odds ratios without adjustment, or reporting significance without absolute risk differences, is the kind of statistical incompleteness that BMJ's statistical desk catches before the paper reaches a clinical reviewer. A BMJ statistical rigor and scope check can assess whether the statistical package meets BMJ's threshold before submission.

If you are considering BMJ, these specific steps improve the submission package before the editor makes the first decision:

• Lead with the clinical or policy consequence, not the method. The first paragraph of your abstract should make the broad use-case visible before the reader reaches the methods.

• Strip away specialty shorthand. If the claim only sounds important after you add subspecialty context, the flagship BMJ audience may be wrong.

• Make the transparency package complete. Reporting checklist, data-sharing statement, ethics details, conflict disclosures, and PPI statement should not look like afterthoughts.

• Use the structured abstract as the desk-screen document. BMJ editors can screen from the abstract, so objectives, design, setting, participants, outcomes, results, and conclusions need specific numbers and a readable implication.

• Write a cover letter that answers "why BMJ?" The answer should be readership and consequence, not brand prestige.